(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 April 2008 (17.04.2008)

PCT

(10) International Publication Number
WO 2008/043774 A1

(51) International Patent Classification:
A61K 39/39 (2006.01) *A61K 39/145* (2006.01)
A61P 31/16 (2006.01) *A61K 39/295* (2006.01)

(21) International Application Number:
PCT/EP2007/060743

(22) International Filing Date: 10 October 2007 (10.10.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0620336.8	12 October 2006 (12.10.2006)	GB
0620337.6	12 October 2006 (12.10.2006)	GB
0620815.1	19 October 2006 (19.10.2006)	GB
0620816.9	19 October 2006 (19.10.2006)	GB
PCT/EP2006/069977	20 December 2006 (20.12.2006)	EP
PCT/EP2006/069979	20 December 2006 (20.12.2006)	EP
0707697.9	20 April 2007 (20.04.2007)	GB
0711357.4	12 June 2007 (12.06.2007)	GB
0712062.9	21 June 2007 (21.06.2007)	GB

(71) Applicant *(for all designated States except US)*: **GLAXOSMITHKLINE BIOLOGICALS S.A.** [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BALLOU, William, Ripley, Jr.** [US/BE]; GlaxoSmithKline Biologicals s.a., rue de l'Institut 89, B-1330 Rixensart (BE). **HANON, Emmanuel, Jules** [BE/BE]; GlaxoSmithKline Biologicals s.a., rue de l'Institut 89, B-1330 Rixensart (BE).

(74) Agents: **JOHNSTON, Caroline, Louise** et al.; Glaxo-SmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(54) Title: VACCINE COMPRISING AN OIL IN WATER EMULSION ADJUVANT

(57) Abstract: The present invention provides an immunogenic composition comprising an antigen or antigen composition and an adjuvant composition comprising an oil in water emulsion, wherein said oil in water emulsion comprises 0.5 - 10 mg metabolisable oil, 0.5 - 11 mg tocol and 0.1 - 4 mg emulsifying agent, per human dose.

WO 2008/043774 A1